Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Beclabuvir in Healthy Subjects
NCT02112110Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of beclabuvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Primary endpoint: Absolute oral bioavailability (F) of BMS-791325 at 48 hours. Started Apr 2014; status: completed.
02
Drugs
beclabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02112110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112110.